nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection
|
Najafi-Fard, Saeid |
|
|
130 |
S1 |
p. S34-S42 |
artikel |
2 |
Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience
|
Saluzzo, Francesca |
|
|
130 |
S1 |
p. S20-S24 |
artikel |
3 |
COVID-19, the escalation of diabetes mellitus and the repercussions on tuberculosis
|
Thong, Pei Min |
|
|
130 |
S1 |
p. S30-S33 |
artikel |
4 |
Editorial Board
|
|
|
|
130 |
S1 |
p. i |
artikel |
5 |
Genomic and geospatial epidemiology of Mycobacterium tuberculosis in Oman: first national insight using whole genome sequencing
|
Al-Jardani, Amina |
|
|
130 |
S1 |
p. S4-S11 |
artikel |
6 |
Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study
|
Nalunjogi, Joanitah |
|
|
130 |
S1 |
p. S25-S29 |
artikel |
7 |
Multidrug-resistant tuberculosis in children: Are the same therapy options available worldwide?
|
Buonsenso, Danilo |
|
|
130 |
S1 |
p. S16-S19 |
artikel |
8 |
Newborn bacille Calmette-Guérin vaccination induces robust infant interferon-γ-expressing natural killer cell responses to mycobacteria
|
Murphy, Melissa |
|
|
130 |
S1 |
p. S52-S62 |
artikel |
9 |
Programmatic management of tuberculosis preventive therapy: Past, present, future
|
Matteelli, Alberto |
|
|
130 |
S1 |
p. S43-S46 |
artikel |
10 |
Supplement Title Page
|
|
|
|
130 |
S1 |
p. ii |
artikel |
11 |
Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
|
Larsen, Sasha E. |
|
|
130 |
S1 |
p. S47-S51 |
artikel |
12 |
Update of drug-resistant tuberculosis treatment guidelines: A turning point
|
Vanino, Elisa |
|
|
130 |
S1 |
p. S12-S15 |
artikel |
13 |
World Tuberculosis Day 2023 theme “Yes! We Can End TB!”
|
Goletti, Delia |
|
|
130 |
S1 |
p. S1-S3 |
artikel |